Citation

McIntyre RS, Mancini DA, Parikh S, Kennedy SH. Can. J. Psychiatry 2001; 46(4): 322-327.

Copyright

(Copyright © 2001, Canadian Psychiatric Association, Publisher SAGE Publications)

DOI

10.1177/070674370104600402

PMID

11387787

Abstract

OBJECTIVE: To review lithium's utility in the treatment of mood disorders.
METHOD: We reviewed the safety, tolerability, teratogenicity, optimal dosing regimens, and mortality-lowering effects of lithium. Clinical relevance and scientific rigour determined which articles we selected for review.
RESULTS: Lithium is the paradigmatic treatment for bipolar disorder (BD). In treating BD, optimal maintenance plasma levels may be approximately 0.75 to 0.85 mEq/L. Although nephrogenic diabetes insipidus is not uncommon, irreversible renal failure due to lithium appears to be a rare, idiosyncratic event. Lithium-induced cardiovascular teratology appears to be less common than previously thought. Optimal lithium dosing may be once daily, this agent appears to bestow a robust suicide-lowering effect, and emerging data hint at neurotrophic and neuroprotective effects.
CONCLUSION: Lithium remains an effective and integral agent in the treatment of BD. Its ability to lower suicide rates in persons with BD warrants clinical attention.

Language: en

Keywords

Adverse Drug Reaction Reporting Systems; Bipolar Disorder; Cause of Death; Humans; Lithium Compounds; Suicide; Suicide Prevention; Treatment Outcome